Muriel Vray

Summary

Publications

  1. ncbi request reprint Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
  2. pmc Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal
    Anna Canestri
    Institut de Médecine et d Epidémiologie Appliquée, Bichat Claude Bernard Hospital, Paris, France
    MedGenMed 9:7. 2007
  3. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
  4. ncbi request reprint Clinically relevant interpretation of genotype for resistance to abacavir
    Francoise Brun-Vezinet
    Department of Virology, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1795-802. 2003
  5. ncbi request reprint Hepatitis B virus exposure during childhood in Cameroon, Central African Republic and Senegal after the integration of HBV vaccine in the expanded program on immunization
    Marie Anne Rey-Cuillé
    From the Unité de Recherche et d Expertise en Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France Institut des Sciences Biologiques, CNRS, Paris, France Service de Virologie, Centre Pasteur du Cameroun, Yaounde, Cameroun Laboratoire des Virus Oncogènes, Institut Pasteur de Bangui, Bangui, République Centrafricaine Laboratoire de Biologie Médicale, Institut Pasteur, Dakar, Sénégal Complexe Pédiatrique, Bangui, République Centrafricaine and Département de virologie, Hopital Saint Louis, Paris, France
    Pediatr Infect Dis J 32:1110-5. 2013
  6. pmc Factors associated with negative direct sputum examination in Asian and African HIV-infected patients with tuberculosis (ANRS 1260)
    Loic Chartier
    Institut Pasteur, Paris, France
    PLoS ONE 6:e21212. 2011
  7. ncbi request reprint Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal
    Roland Landman
    Institut de Médecine et d Epidémiologie Africaine, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1017-22. 2003
  8. doi request reprint Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays
    Jean Marie Sire
    Laboratoire de Virologie, Hôpital Saint Louis AP HP, INSERM U941, Universite Paris Diderot, Paris, France
    J Acquir Immune Defic Syndr 56:239-43. 2011
  9. pmc Higher specificity of nucleic acid sequence-based amplification isothermal technology than of real-time PCR for quantification of HIV-1 RNA on dried blood spots
    Séverine Mercier-Delarue
    Laboratoire de Virologie, AP HP Hôpital Saint Louis, INSERM U941 Université Paris Diderot, Sorbonne Paris Cité, Paris, France
    J Clin Microbiol 52:52-6. 2014
  10. ncbi request reprint Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)
    Roland Tubiana
    Departement des Maladies Infectieuses et Tropicales, INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    Vaccine 23:4292-301. 2005

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
    ..To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed...
  2. pmc Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal
    Anna Canestri
    Institut de Médecine et d Epidémiologie Appliquée, Bichat Claude Bernard Hospital, Paris, France
    MedGenMed 9:7. 2007
    ..To study the effectiveness and tolerance of an antiretroviral therapy (ART) regimen composed of the antiretroviral agents (ARVs) stavudine (d4T) plus didanosine (ddI) plus efavirenz (EFV) in patients with advanced HIV infection in Senegal...
  3. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
    ..To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens...
  4. ncbi request reprint Clinically relevant interpretation of genotype for resistance to abacavir
    Francoise Brun-Vezinet
    Department of Virology, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1795-802. 2003
    ..To develop a stepwise methodology for the development and validation of clinically relevant genotypic score for resistance to antiretroviral drugs and to apply this approach to the genotypic resistance to abacavir...
  5. ncbi request reprint Hepatitis B virus exposure during childhood in Cameroon, Central African Republic and Senegal after the integration of HBV vaccine in the expanded program on immunization
    Marie Anne Rey-Cuillé
    From the Unité de Recherche et d Expertise en Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France Institut des Sciences Biologiques, CNRS, Paris, France Service de Virologie, Centre Pasteur du Cameroun, Yaounde, Cameroun Laboratoire des Virus Oncogènes, Institut Pasteur de Bangui, Bangui, République Centrafricaine Laboratoire de Biologie Médicale, Institut Pasteur, Dakar, Sénégal Complexe Pédiatrique, Bangui, République Centrafricaine and Département de virologie, Hopital Saint Louis, Paris, France
    Pediatr Infect Dis J 32:1110-5. 2013
    ..We evaluated the prevalence of HBV exposure and infection after the integration of the HBV vaccine in the EPI...
  6. pmc Factors associated with negative direct sputum examination in Asian and African HIV-infected patients with tuberculosis (ANRS 1260)
    Loic Chartier
    Institut Pasteur, Paris, France
    PLoS ONE 6:e21212. 2011
    ..To identify factors associated with negative direct sputum examination among African and Cambodian patients co-infected by Mycobacterium tuberculosis and HIV...
  7. ncbi request reprint Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal
    Roland Landman
    Institut de Médecine et d Epidémiologie Africaine, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1017-22. 2003
    ..To study the effectiveness, adherence and tolerance of a once-a-day highly active antiretroviral therapy regimen in adults in Senegal...
  8. doi request reprint Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays
    Jean Marie Sire
    Laboratoire de Virologie, Hôpital Saint Louis AP HP, INSERM U941, Universite Paris Diderot, Paris, France
    J Acquir Immune Defic Syndr 56:239-43. 2011
    ..A new version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay (CA/CTM v2.0) has been introduced to overcome the underquantification observed with the first version...
  9. pmc Higher specificity of nucleic acid sequence-based amplification isothermal technology than of real-time PCR for quantification of HIV-1 RNA on dried blood spots
    Séverine Mercier-Delarue
    Laboratoire de Virologie, AP HP Hôpital Saint Louis, INSERM U941 Université Paris Diderot, Sorbonne Paris Cité, Paris, France
    J Clin Microbiol 52:52-6. 2014
    ..This higher specificity of NASBA technology could avoid overestimation of poor compliance or the emergence of resistance when monitoring antiretroviral efficacy with the DBS method. ..
  10. ncbi request reprint Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)
    Roland Tubiana
    Departement des Maladies Infectieuses et Tropicales, INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    Vaccine 23:4292-301. 2005
    ..Detection of such LPR response at the time of treatment interruption was significantly associated with the probability of remaining off therapy. These results provide rationale for future randomized trials exploring this strategy...
  11. ncbi request reprint Good clinical practice in developing countries: applying recommendations
    Francois Bompart
    Direction Accès au Médicament, Sanofi Aventis, Paris, France
    Therapie 63:83-8, 77-82. 2008
    ....
  12. ncbi request reprint Molecular epidemiology of hepatitis B virus in Dakar, Sénégal
    Muriel Vray
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    J Med Virol 78:329-34. 2006
    ..These results underline the importance of molecular characterization of HBV infection as specific treatments become available in this region...
  13. doi request reprint Clinical trials and E-health: impact of new information technology applied to clinical trials (including source data-medical records) and to human and drug research
    Jehan Michel Behier
    Laboratoires MSD Chibret, Paris, France
    Therapie 65:317-22, 309-15. 2010
    ..Finally, the impact of these new technologies on the investigator as well as the project manager was analysed...
  14. ncbi request reprint Guidelines for clinical research in developing countries
    Muriel Vray
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    Therapie 62:217-27. 2007
    ..In addition, an independent Data Safety Monitoring Board should be set up and systems established to ensure the effective reporting of Serious Adverse Events and to specify the Sponsor's obligations after the end of the Study...
  15. doi request reprint Evaluation of an in-house ELISA using the intermediate species Leptospira fainei for diagnosis of leptospirosis
    Pascale Bourhy
    Institut Pasteur, Biology of Spirochetes Unit, National Reference Center and WHO Collaborating Center for Leptospirosis, Paris, France
    J Med Microbiol 62:822-7. 2013
    ..The overall performance of this in-house ELISA suggests applicability as a rapid screening test for the diagnosis of leptospirosis in resource-limited settings and in hospitals and laboratories where a MAT is not available...
  16. doi request reprint [French Health Authority (HAS) Guidance: the post-registration studies on health technologies (drugs, medical devices and instruments): principles and methods]
    Sophie Stamenkovic
    Unité Méthodologie et Études Post Inscription, Direction de l Évaluation Médico Économique et de Santé Publique, HAS, Paris, France
    Therapie 67:409-21. 2012
    ..The publication of the results of these studies is strongly encouraged...
  17. pmc Low immune response to hepatitis B vaccine among children in Dakar, Senegal
    Marie Anne Rey-Cuillé
    Unité de Recherche et d Expertise en Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    PLoS ONE 7:e38153. 2012
    ..Field biological monitoring should be carried out regularly in resource-poor countries to check quality of the vaccine administered...
  18. ncbi request reprint [Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat]
    Muriel Vray
    Institut Pasteur, Bâtiment Laveran, Paris, France
    Therapie 60:17-24. 2005
    ..The treatment cost was the main reason for definitive treatment discontinuation for more than 50% of the patients. The average weight loss was 5% and 9% after 3 and 12 months of treatment, respectively...
  19. doi request reprint Predictors of pneumocystosis or tuberculosis in HIV-infected Asian patients with AFB smear-negative sputum pneumonia
    Odile Le Minor
    Institut Pasteur, Paris, France
    J Acquir Immune Defic Syndr 48:620-7. 2008
    ..To identify predictors of Pneumocystis jiroveci pneumonia (PCP) or pulmonary tuberculosis (TB) in acid-fast bacillus smear-negative HIV-infected patients and to develop clinical prediction rules...
  20. ncbi request reprint Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa
    Jean Pierre Lombart
    Hôpital Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso
    AIDS 19:1273-7. 2005
    ..In resource-limited settings, the requirement for inexpensive, easy-to-perform viral load monitoring has increased with greater antiretroviral drug availability...
  21. ncbi request reprint Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 11:421-9. 2006
    ....
  22. ncbi request reprint Identification of hepatitis B virus subgenotype A3 in rural Gabon
    Maria Makuwa
    Laboratoire de Retrovirologie, Centre International de Recherches Medicales, CIRMF, Franceville, Gabon
    J Med Virol 78:1175-84. 2006
    ..Two full genome sequences of two new Gabonese HBV isolates are also presented and confirm the distinctive HBV-Gab-A3 cluster...
  23. ncbi request reprint Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes
    Marie Gueudin
    Laboratoire de Virologie, Equipe d accueil 2656, Centre Hospitalier Universitaire Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Acquir Immune Defic Syndr 44:500-5. 2007
    ..We also tested 88 plasma samples from patients infected with HIV-1 group M (B-D [n = 7], A-CRF01 [n = 16], CRF02 [n = 49], and other strains [n = 16])...